Effectiveness of pathogenetic therapy for infectious diarrhea in children with COVID-19
https://doi.org/10.21518/2079-701X-2020-18-95-100
Abstract
Introduction. The article presents basic information on approaches to pathogenetic therapy of acute intestinal infections. Data from our own research on the diagnosis and treatment of gastrointestinal manifestations of COVID-19 in children aged 3 months to 18 years are presented. The aim of the study was to evaluate the effectiveness of complex rehydration, cytomucoprotective and probiotic therapy for infectious diarrhea of various etiologies, including those developing with a new coronavirus infection.
Materials and methods. We analyzed data from our own observations of patients aged 3 months to 18 years with diarrhea against the background of acute intestinal infections of various etiologies (120 children), as well as with a new coronavirus infection caused by the SARS-CoV-2 virus (32 children). The children were treated in accordance with current standards and treatment recommendations. Clinical examples are presented.
Results and discussion. Diarrhea was observed in 64% of patients with a new coronavirus infection. Clinical cases confirm the effectiveness of rehydration, cytomucoprotective and probiotic therapy for infectious diarrhea, regardless of the etiology, including COVID-19.
Conclusions. Diarrhoea and other symptoms of gastrointestinal disorders in COVID-19 are stopped when pathogenetic therapy is recommended for patients with acute intestinal infections.
About the Authors
D. A. Khavkina
Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Statistic of clinical research Department, Federal Budget Institution of Science “Central Research Institute of Epidemiology”
3a, Novogireevskaya St., Moscow, 111123, Russia
T. A. Ruzhentsova
Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Head of clinical research Department, Professor of Educational Center
3a, Novogireevskaya St., Moscow, 111123, Russia
R. V. Popova
Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance;
State Budgetary Healthcare Institution of the Moscow region “Mytishchi city clinical hospital”
Russian Federation
Russian Federation
Laboratory-assistant – researcher of the clinical Department of infectious pathology; pediatrician
3a, Novogireevskaya St., Moscow, 111123, Russia
24, Comintern St., Mytischi, Moscow region, 141009, Russia
P. V. Chukhlyaev
Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Methodist of clinical research Department
3a, Novogireevskaya St., Moscow, 111123, Russia
A. A. Garbuzov
Federal Budget Institution of Science “Central Research Institute of
Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Methodist of clinical research Department
3a, Novogireevskaya St., Moscow, 111123, Russia
N. A. Meshkova
Federal State Autonomous Educational Institution of Higher Education “Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Student of 3th course, Institut of Children’s Health
2, Bldg. 4, B. Pirogovskaya St., Moscow, 119991, Russia
References
1. Xiao F., Tang M., Zheng X., Liu Y., Li X., Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–1833.e3. doi: 10.1053/j.gastro.2020.02.055.
2. Lu X., Zhang L., Du H., Zhang J., Li Y.Y., Qu J. et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–1665. doi: 10.1056/NEJMc2005073.
3. Khavkina D.A., Ruzhencova Т.А., Chukhliaev P.V., Garbuzov А.А., Shushakova Е.К. The role of detoxication and antioxidation therapy СOVID-19: theory and practiceа. Ehpidemiologiya i infektsionnye bolezni: aktualnye voprosy = Epidemiology and Infection Diseases: Actual Questions. 2020:62–69. (In Russ.) doi: 10.18565/epidem.2020.2.62-69.
4. Tang X., Wu C., Li X., Song Yu., Yao X., Wu X. et al. On the origin and continuing evolution of SARS-CoV-2. National Science Review. 2020;7(6):1012–1023. doi: 10.1093/nsr/nwaa036.
5. Ruzhentsova T.A., Gorelov A.V., Ploskireva A.A., Usenko D.V. Initial therapy of acute diarrhea in children. RMZH = RMJ. 2015;(14):830–833. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Startovaya_terapiya_ostroy_diarei_u_detey.
6. Ploskireva A.A., Gorelov A.V. Pathogenetic therapy of acute intestinal infections in children: integrated approach. RMZH = RMJ. 2018;(8(II)):79–82. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Patogeneticheskaya_terapiya_ostryh_kishechnyh_infekciy_u_detey_kompleksnyy_podhod.
7. Frasca G., Cardile V., Puglia C., Bonina C., Bonina F. Gelatin tannate reduces the proin-flammatory effects of lipopolysaccharide in human intestinal epithelial cells. Clin Exp Gastroenterol. 2012;5:61–67. doi: 10.2147/CEG.S28792.
8. Esteban Carretero J., Durbán Reguera F., López-Argüeta Alvarez S., López Montes J. A comparative analysis of response to vs. ORS + gelatin tannate pediatric patients with acute diarrhea. Rev Esp Enferm Dig. 2009;101(1):41–48. doi: 10.4321/s1130-01082009000100005.
9. Allegrini A., Costantini M. Gelatine Tannate for the Treatment of Acute Diarrhoea in Adults. J Gastrointest Dig Syst. 2012;2:110. doi: 10.4172/2161-069X.1000110.
10. Loeb H., Vandenplas E., Wursch P., Guesry P. Tannin-rich carob pod for the treatment of acute-onset diarrhea. J Pediatr Gastroenterol Nutr. 1989;8(4):480–485. doi: 10.1097/00005176-198905000-00010.
11. Khaliullina S.V., Anokhin V.A., Urmancheeva Yu.R., Sushnikov K.V., Nurgalieva N.M., Cherepanova L.A. A prospective open comparative randomized study of the effectiveness of gelatine tannate for treatment of acute diarrhoeas in children. Voprosy prakticheskoy pediatrii = Clinical Practice in Pediatrics. 2014;9(1):24–28. (In Russ.) Available at: https://www.phdynasty.ru/en/catalog/magazines/clinical-practice-in-pediatrics/2014/volume-9-issue-1/12067.
12. Bekhtereva M.K., Komarova A.M., Uskov A.N., Razdyakonov I.V., Alekseeva L.A., Bessonova Т.V. Еffectiveness of Gelatin tannate in acute infectious diarrhea in children. Detskie Infektsii = Children’s Infections. 2017;16(4):58-63. (In Russ.) Available at: https://elibrary.ru/item.asp?id=30635504.
13. Loverdo R.G., Solovyev Yu.V., Shtokаlov K.G., Sulima N.N. Experience in the use and evaluation of the effectiveness of gelatinе tannatе in the treatment of acute intestinal infections in children. Detskie Infektsii = Children’s Infections. 2019;18(1):38–41. (In Russ.) Available at: https://elibrary.ru/item.asp?id=37392289.
Review
For citations:
Khavkina DA, Ruzhentsova TA, Popova RV, Chukhlyaev PV, Garbuzov AA, Meshkova NA. Effectiveness of pathogenetic therapy for infectious diarrhea in children with COVID-19. Meditsinskiy sovet = Medical Council. 2020;(18):95-100. (In Russ.) https://doi.org/10.21518/2079-701X-2020-18-95-100
Views:
813
Email this article 